Aldeyra Therapeutics, Inc.
ALDXAldeyra Therapeutics, Inc. is a biotechnology company focused on developing treatments for immune-mediated diseases and immune system-related conditions. Its portfolio includes therapies aimed at modulating immune responses to address conditions such as dry eye disease, allergic conjunctivitis, and other inflammatory disorders. The company leverages its proprietary immune modulator platform to explore potential treatments across various therapeutic areas.
Company News
Levicept Ltd announces the appointment of Darlene Deptula-Hicks as Chief Financial Officer. Deptula-Hicks brings extensive biotechnology and pharmaceutical industry experience, including successful capital raises and a Nasdaq listing at F-star Therapeutics. The appointment strengthens Levicept's senior team as the company advances late-stage deve...
The Rosen Law Firm reminds investors in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) of the May 29, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that defendants made false statements regarding inconsistent clinical trial results for reproxalap and failed to disclose material information about the company's business an...
Rosen Law Firm is notifying investors in Babcock & Wilcox Enterprises, Aldeyra Therapeutics, and ChampionX Corporation of ongoing securities class action lawsuits. The B&W lawsuit alleges the company made false statements regarding a Power Generation contract with Applied Digital, with its largest shareholder BRC standing on both sides of the dea...
A class action lawsuit has been filed against Aldeyra Therapeutics (ALDX) for allegedly issuing false and misleading statements regarding reproxalap clinical trial results. The lawsuit claims the trial results were inconsistent and unreliable. Investors who purchased shares between November 3, 2023 and March 16, 2026 have until May 29, 2026 to ap...
Rosen Law Firm reminds investors in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) who purchased securities between November 3, 2023 and March 16, 2026 of the May 29, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that defendants made false statements regarding reproxalap clinical trial results and failed to disclose inco...
